Recommendations for the collection and annotation of biosamples for analysis of biomarkers in neurofibromatosis and schwannomatosis clinical trials.

R Taylor SundbySteven D RhodesEdina Komlodi-PasztorHerb SarnoffVito GrassoMeena UpadhyayaAeRang KimD Gareth EvansJaishri O BlakeleyC Oliver HanemannChetan Bettegowda

Published in: Clinical trials (London, England) (2023)

These Response Evaluation in Neurofibromatosis and Schwannomatosis consensus guidelines are intended to provide best practices for the inclusion of biomarker studies in neurofibromatosis 1/schwannomatosis clinical trials, data, and sample annotation and to lay a framework for data harmonization and concatenation between trials.

Keyphrases

clinical trial
clinical practice
electronic health record
big data
primary care
healthcare
phase ii
rna seq
randomized controlled trial
study protocol
machine learning
open label
single cell
artificial intelligence